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SomatostatinIn the present study, we describe the role of cytoplasmic terminal (C-tail) domain in regulating coupling to
adenylyl cyclase, signaling, and apoptosis in human embryonic kidney (HEK-293) cells transfected with wild
type (wt)-hSSTR3 and C-tail deleted mutants. Cells transfected with wt-hSSTR3 and C-tail mutants show
comparable membrane expression; however, display decreased expression in presence of agonist. wt-hSSTR3
exists as preformed homodimer at cell surface in basal conditions and decreases in response to agonist. Cells
expressing C-tail mutants also show evidence of homodimerization with the same intensity as wt-hSSTR3.
The agonist-dependent inhibition of cyclic adenosine monophosphate (cAMP) was lost in cells expressing C-
tail mutants. Agonist treatment in cells expressing wt-hSSTR3 resulted in inhibition of cell proliferation,
increased expression of PARP-1, and TUNEL positivity in proliferating cell nuclear antigen (PCNA)-positive
cells. The agonist mediated increase inmembrane expression of protein tyrosine phosphatase (PTP) seenwith
wt-hSSTR3 was diminished in C-tail mutants, which was accompanied with the loss of receptor's ability to
induce apoptosis. Taken together, our data provide new insights into C-tail-dependent regulation of cell
signaling and apoptosis by hSSTR3.osine monophosphate; C-tail,
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G-protein-coupled receptors (GPCRs) represent one of the largest
and most diverse families of cell surface proteins, which are known to
play important roles in a variety of pathological conditions. Most of
the current therapeutic drugs target GPCRs, implicating their clinical
importance in the pathogenesis of various diseases [1–4]. Somato-
statin (SST) is a multifunctional regulatory peptide secreted by
endocrine, neuronal, and immune cells and acts to regulate cell
secretion, neurotransmission, and cell proliferation [5]. These distinct
and diverse biological effects of SST are mediated via ﬁve different
receptor subtypes namely somatostatin receptors (SSTR1–5), which
belong to GPCR family and are widely distributed and highly
expressed in normal as well as in several pathological conditions [6].
Structure–function studies have shown great diversity among SSTRsubtypes [5,7–14]. All ﬁve SSTRs are known to inhibit adenylyl cyclase
(AC), a key intracellular signal transducer through Gαi/o subunits
[5,11]. C-tail of SSTRs has been shown to play a critical role in cAMP
inhibition. We have previously shown that C-tail deleted mutants of
human (h) SSTR5 and SSTR4 failed to inhibit forskolin (FSK)-
stimulated cAMP [7,8,14].
Several previous studies have emphasized the importance of GPCR
dimerization in receptor-biogenesis, regulation, and pharmacology
[15–17]. SSTRs form homo- and heterodimers within the same family
as well as with other related GPCRs and members of receptor tyrosine
kinase family [7–11,13,14,17,18]. It has been shown previously that
rat (r) SSTR3 exists as homodimer and also heterodimerize with
rSSTR2 with the functional activity of rSSTR2 whereas rSSTR3-like
properties were abrogated [9].
Despite detailed pharmacological characterization of homo- and
heterodimerization, very little is known about the role of GPCRs in the
regulation of physiological response of the cells and mitogen-
activated protein kinases (MAPKs) signaling modulating cell prolif-
eration, differentiation, and migration [19]. The phosphorylation of
ERK1/2 is known to be involved in cell proliferation; however, ERK1/2
has been also shown to regulate the cell proliferation during G1/GS
cell-cycle transition induced by the EGF [18,19]. SSTRs are known to
differentially regulate the ERKs in a receptor-speciﬁc manner
[5,14,17,20,21]. SSTR1, SSTR2, and SSTR4 stimulate ERK phosphory-
lation, whereas SSTR5 inhibits it [14,17,22–24]. SSTR3 upon activation
may stimulate or inhibit the ERK phosphorylation depending upon
the cell type [5,9,20,23].
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dependant manner, and the antiproliferative mechanism may be
cytostatic or cytotoxic [5,21,25–28]. In particular, SSTR3 mediated
pro-apoptotic effects involve translocation of PTP to cell membrane,
and p53 activation [26,29]. These unique antiproliferative charac-
teristics of SST have been exploited in the treatment of various
tumors. Previously, it was shown that C-tail of hSSTR5 is critical in
mediating the SST-analogue-induced cytostatic activity, and there
was loss of antiproliferative effect proportional to amino acids
deleted from the C-tail [28]. Our recent study has described the role
of hSSTR4 C-tail in modulating various downstream signaling
cascades [14]. However, the role of C-tail in regulating hSSTR3-
mediated downstream signaling and antiproliferative effects is not
known. In the present study, taking advantage of the morphological,
biochemical, and biophysical techniques, we describe the role of C-
tail of hSSTR3 on receptor expression, coupling to AC, downstream
signaling pathways, and cell proliferation in HEK-293 cells trans-
fected with wt-hSSTR3 as well as four C-tail deleted hSSTR3
mutants. Here, we have demonstrated for the ﬁrst time that
hSSTR3 signaling and antiproliferative effects are dependent on
amino acid (aa) residues present in the C-tail.
2. Materials and methods
2.1. Materials
SST-14 and Leu8-D-Trp22-Tyr25 SST-28 were purchased from
Bachem, Torrance, CA. The SSTR3 selective non-peptide agonist L-
796778 was kindly provided by Dr. S.P. Rohrer from Merck & Co [30].
Rabbit polyclonal anti-SSTR3 antibodywas purchased from Santa Cruz
Biotechnology Inc. Santa Cruz, CA. Fluorescein/Rhodamine-conjugat-
ed mouse monoclonal antibodies against hemagglutinin (HA) and
TUNEL kit were purchased from La Roche Applied Science, Mannheim,
Germany. Mouse monoclonal anti-PARP-1 and PTP-1C antibodies
were purchased from BD-Biosciences, Mississauga, ON. Rabbit
polyclonal antibodies for total and phospho (p)-ERK1/2 were
purchased from Cell Signaling Technology, Danvers, MA. Fluorescein
and rhodamine or peroxidase conjugated goat anti-mouse and goat
anti-rabbit secondary antibodies were purchased from Jackson
ImmunoResearch Laboratories, West Grove, PA. Mouse monoclonal
anti-PCNA and β-actin antibodies were purchased from Sigma-
Aldrich Inc., St. Louis, MO. cAMP kit was purchased from BioVision,
Inc. CA, USA. ECLWestern blotting detection kit and nitrocellulose Hy-
Bond ECL membrane were purchased from Amersham Ltd., Oakdale,
ON. Dulbecco's modiﬁed eagle medium (DMEM), trypsin-EDTA,
Dulbecco's phosphate-buffered saline (D-PBS) were purchased from
Invitrogen, Burlington, ON, Canada. Reagents for electrophoresis were
purchased from BIO-RAD Laboratories Mississauga ON. Other reagents
were of AR grade and were purchased from various sources.Fig. 1. Illustration of hSSTR3 structure. Schematic representation of 418 aa hSSTR3 and the am
Δ415), 30 aa (R3 Δ388), 76 aa (R3 Δ342), and 100 aa (R3 ΔCT)].2.2. hSSTR3 constructs and transfection
Constructs of wt-hSSTR3, N-terminal HA-tagged hSSTR3 (HA-
hSSTR3) and four differentmutants of hSSTR3 (Fig. 1) with amino acid
deletions in the C-tail; 3 aa (R3 Δ415), 30 aa (R3 Δ388), 76 aa (R3
Δ342), and 100 aa (complete C-tail deletion or R3 ΔCT) were made
using pCDNA3.1/Neo (neomycin resistance) as previously described
[11,14]. HEK-293 cells expressing wt-hSSTR3, HA-hSSTR3, and C-tail
mutants were stably transfected using Lipofectamine transfection
reagent as described earlier [11]. Clones were selected and main-
tained in DMEM with 10% fetal bovine serum (FBS) and 700 μg/ml
neomycin.
2.3. Binding analysis
HEK-293 cells expressing wt-hSSTR3 and mutants were grown to
70–80% conﬂuency, and membrane was prepared and processed for
binding studies. Brieﬂy, 20–40 μg of membrane protein was used and
incubated with radiolabelled SST-28 for 30 min at 37 °C as previously
described [17]. Saturation binding experiments were performed with
membranes using increasing ligand concentrations under equilibrium
binding conditions. Incubations were terminated by the addition of
1 ml ice-cold D-PBS containing 0.2% bovine serum albumin, rapid
centrifugation, and washing. Radioactivity was measured with a LKB
gamma counter (LKBWallach, Turku, Finland). The dissociation
constant (Kd) and the number of SST-28 binding sites (Bmax) were
calculated and analyzed with Graph Pad Software, San Diego, CA.
2.4. Receptor coupling to adenylyl cyclase
To determine the receptor coupling to AC, HEK-293 cells stably
expressing wt-hSSTR3 and different C-tail mutants were grown in 96-
well plates and used at 70% cell conﬂuency for cAMP assay as
described previously [14]. Brieﬂy, cells were treated for 30 min with
FSK (20 μM) and 3-isobutyl-1-methylxanthine (0.5 mM) in the
presence or absence of SST-14 (1 μM) or L-796778 (50 nM) at 37 °C.
Cells were then scraped in HCl (0.1 N), and FSK-stimulated cAMP was
determined by immunoassay using a cAMP Kit according to the
manufacturer's guidelines.
2.5. hSSTR3 membrane expression and agonist-induced internalization
To study hSSTR3 membrane expression and receptor internaliza-
tion, HEK-293 cells expressing wt-hSSTR3 and C-tail mutants were
grown on poly-D-lysine coated glass coverslips to 60–70% conﬂuency
and then treated with SST-14 (1 μM) or L-796778 (50 nM) for 15 min
at 37 °C. Treatment was terminated with ice-cold D-PBS, and the cells
were ﬁxed with 4% paraformaldehyde for 15 min at room tempera-
ture (RT). For membrane and cytosolic expression, cells were treatedino acid sequence in its C-tail, and the sites for truncation of C-tail amino acids [3 aa (R3
Table 1
Binding characteristics of wt-hSSTR3 and C-tail mutants.
Receptor Kd (nM) Bmax (fmol/mg of protein)
wt-hSSTR3 1.2±0.21 285±10
R3 Δ415 1.4±0.28 292±19
R3 Δ388 1.5±0.31 315±11
R3 Δ342 1.8±0.38 260±17
R3 ΔCT 1.5±0.36 255±13
Data shown in the table represents mean±SE of three independent experiments.
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and then processed for indirect immunoﬂuorescence immunocyto-
chemistry using rabbit polyclonal anti-SSTR3 antibodies. Receptor
expression in non-permeabilized and permeabilized cells was
analyzed under Leica TCS SPE Confocal Microscope. Adobe Photoshop
was used for making composites.
2.6. Photobleaching–ﬂuorescence resonance energy transfer (Pb–FRET)
analysis
To determine hSSTR3 homodimerization, microscopic Pb–FRET
analysis was performed in HEK-293 cells expressing HA-hSSTR3
(Bmax, 285±10 fmol/mg protein; Kd, 1.2±0.21 nM) as previously
described [11]. Brieﬂy, cells were grown on poly-D-lysine coated glass
coverslips to 60–70% conﬂuency and treated with SST-14 (1 μM) or L-
796778 (50 nM) for 10 min at 37 °C, and ﬁxed with 4% paraformal-
dehyde for 15 min at RT. Following three subsequentwashes in D-PBS,
cells were incubated with FITC conjugated anti-HA antibody and
rhodamine-conjugated anti-HA antibody for donor and acceptor pair,
respectively. The plasma membrane region was used to analyze the
photobleaching decay on a pixel-by-pixel basis. The FRET efﬁciency
(E) was calculated as a percent based upon the photo bleaching time
constants of the donor taken in the absence (D−A) and presence (D
+A) of acceptor. The effective FRET efﬁciency (E) was calculated
according to the formula E=[1−(D−A/D+A)]×100 [14]. Adobe
Photoshop and Image J software, NIH, were used make composites.
2.7. Western blot analysis
To determine homodimerization, cells expressing wt-hSSTR3 and
C-tail mutants were treated with SST-14 (1 μM) and L-796778
(50 nM) for 15 min at 37 °C. Cell lysate was prepared and processed
for Western blot analysis using SSTR3 antibody (1:500 dilution) as
previously described [11,14]. For other procedures like membrane
blocking, primary and secondary antibody incubation, and chemilu-
minescence detection, the manufacturer's instructions were followed.
Images were captured with an Alpha Innotech FluorChem 8800 gel
box imager (Alpha Innotech Co., San Leandro, CA). To standardize for
protein loading, all membranes were reprobed for beta-actin.
Immunoblotting for ERK1/2 and PARP-1 was performed using
speciﬁc antibodies. Cells stably expressing wt-hSSTR3 and C-tail
mutants were treated with SST-14 (1 μM) or L-796778 (50 nM) at
37 °C for 5 or 15 min. For PARP-1 expression, cells were treated with
L-796778 (50 nM) for 24 h at 37 °C. Reaction was terminated by using
ice-cold D-PBS and cells were collected and homogenized in radio-
immune precipitation assay (RIPA) buffer (150 mM NaCl, 50 mM
Tris–HCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate,
protease and phosphatase inhibitors 1:100, pH 8.0). Cell lysate was
prepared and probed for total and p-ERK1/2 using speciﬁc antibodies
(1:1000 dilution). For PARP-1 expression, antibody dilution was
1:5000.
To estimate the membrane and cytosolic expression of PTP-1C,
cells expressing wt-hSSTR3 and C-tail mutants were treated with SST-
14 (1 μM) or L-796778 (50 nM) for 15 min at 37 °C. Cell lysate was
centrifuged at 10,000g for 1 h at 4 °C. The membrane and cytosolic
fractions were fractionated on 10% SDS-PAGE and processed for PTP-
1C expression using monoclonal anti-PTP-1C antibody (1:500
dilution). β-Actin was used as loading control.
Densitometric analysis on all the bands was performed by using
FluorChem software (Alpha Innotech).
2.8. Cell proliferation assay
To characterize the antiproliferative role of hSSTR3, non-trans-
fected HEK-293 cells or cells expressingwt-hSSTR3 and C-tail mutants
were seeded at a density of 5000 cells/well in 96-well plates andallowed to grow for 24 h. Cells were then serum deprived (without
FBS) for 24 h followed by treatment with SST-14 (1 μM) and L-796778
(50 nM) in the presence of 5% FBS for 24 h. As a control, cells were
supplemented only with FBS to compare for the normal cell growth.
Conventional MTT [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide)] assay protocol was used to measure the cell
viability. Brieﬂy, 20 μl of 5 mg/ml MTT solution was added and
incubated for 2 h at 37 °C in a humidiﬁed atmosphere containing 5%
CO2. The formazan precipitate formed was dissolved in 200 μl of
isopropanol. The absorbance was measured in a microplate spectro-
photometer at 550 nm.
2.9. PCNA immunoﬂuorescence and TUNEL staining
To characterize the cells susceptible to apoptosis, cells expressing
wt-hSSTR3 and C-tail mutants were grown on poly-D-lysine coated
glass coverslips to 60-70% conﬂuency followed by treatment with
SST-14 (1 μM) or L-796778 (50 nM) for 24 h. Cells were permeabi-
lized using 0.3% Triton X-100 and then incubated overnight at 4 °C
with monoclonal anti-PCNA primary antibody followed by Cy3-
conjugated secondary antibody for 1 h at RT. The coverslips were
washed in D-PBS and were further incubated with TUNEL reaction
mixture for 1 h at 37 °C in a humidiﬁed atmosphere in dark. Following
subsequent washes in D-PBS, the coverslips were mounted on glass
slides and analyzed under Leica ﬂuorescence microscope. Adobe
Photoshop was utilized for making composites, and merged images
illustrating colocalization were generated by using Image J software,
NIH.
2.10. Statistical analysis
Results are presented as mean±SE unless otherwise stated.
Statistical analysis was carried out using Graph Pad Prism 4.0 as
indicated and statistical differences were taken at p valuesb0.05.
3. Results
3.1. Binding analysis of wt-hSSTR3 and mutants
The membrane expression of wt-hSSTR3 and C-tail mutants was
determined by binding analysis using radiolabelled SST-28 as
described in Materials and methods. As shown in Table 1, saturation
analysis indicates high expression of wt-hSSTR3 (Bmax, 285±10 fmol/
mg of protein; Kd, 1.2±0.21 nM) at the plasma membrane. As
compared to the wt-hSSTR3, the C-tail mutants displayed marginal
changes in receptor density at the cell surface and the differences
were statistically insigniﬁcant. These results suggest that C-tail
deletion had no signiﬁcant effect on hSSTR3 cell surface expression.
3.2. hSSTR3 membrane expression and agonist-induced internalization
Previous studies have shown that among all hSSTR subtypes,
hSSTR3 internalized the most in a time and temperature-dependent
manner and does not recycle back to the cell membrane, rather
targeted for degradation [31]. As shown in Fig. 2 and Table 2, the
Table 2
Semi-quantitative analysis of receptor-like immunoreactivity in HEK-293 cells
transfected with wt-hSSTR3 and C-tail mutants and treated with SST-14- and SSTR3-
speciﬁc agonist, L-796778 for 15 min at 37 °C.
Condition wt-hSSTR3 R3 Δ415 R3 Δ388 R3 Δ342 R3 ΔCT
NP P NP P NP P NP P NP P
Control ++ ++ ++ ++ ++ ++ + ++ + ++
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and intracellularly in cells expressing wt-hSSTR3, whereas upon
treatment with SST-14 and L-796778, in the receptor-speciﬁc agonist,
there was loss of receptor expression at the cell surface. In C-tail
mutants (R3 Δ415, R3 Δ388, R3 Δ342, and R3 ΔCT), the receptor
expression at the cell surface was not signiﬁcantly different when
compared with wt-hSSTR3. However, upon treatment with agonist,Fig. 2. Representative photomicrographs illustrating the expression and internalization
of hSSTR3. Cells transfected with wt-hSSTR3 and C-tail mutants were treated with SST-
14 (1 μM) and L-796778 (50nM) for 15 min at 37 °C, and processed for membrane and
intracellular expression in non-permeabilized (NP) and permeabilized (P) cells using
indirect immunoﬂuorescence immunocytochemistry. Note the comparable receptor
expression at the cell surface between wt-hSSTR3 and C-tail mutants. In cells
expressing wt-hSSTR3 and C-tail mutants, the receptor-like immunoreactivity was
decreased at plasma membrane upon agonist treatment. Data are presented as mean
±SE of three independent experiments. Scale bar=10 μm.
+ + + + + + + +
SST-14 (1 μM) ++ ++
+
++ ++
+
++ ++
+
+
+
++
+
+
+
++
+
L - 7 9 6 7 7 8
(50 nM)
++ ++
+
++ ++
+
++ ++
+
+
+
++
+
+
+
++
+
NP=non-permeabilized cells. P=permeabilized cells. Values are ranked as follows:
+++ strongly positive and ++ moderately positive. Immunoreactivity ranged on
the basis of intensity of receptor-like immunoreactivity as determined by using NIH
Image J.receptor displayed signiﬁcant internalization. These results suggest
that C-tail does not play determinant role on receptor internalization.
3.3. Receptor coupling to adenylyl cyclase is disrupted upon hSSTR3
C-tail deletions
All SSTRs are known to inhibit AC, whether hSSTR3 coupling to AC
is impaired in C-tail mutants is not known. Accordingly, we next
examined the role of SST-14 and SSTR-speciﬁc agonist on inhibition of
FSK-stimulated cAMP in cells expressing wt-hSSTR3 and different
mutants. The inhibition of cAMP by SSTR3 is a direct measure of
receptor functions. Cells were treated with SST-14 (1 μM) and L-
796778 (50 nM) for 30 min at 37 °C. As shown in Fig. 3, FSK-
stimulated cAMP in cells expressing wt-hSSTR3 was inhibited by 52%
and 51% upon treatment with SST-14 (1 μM) and L-796778 (50 nM),
respectively. In C-tail mutants, there was a gradual loss of agonist
mediated inhibition of cAMP, which was proportional to the amino
acids deleted. Consistent with our previous studies, these results
implicate the importance of C-tail in mediating agonist-induced cAMP
inhibition.Fig. 3. Receptor coupling to adenylyl cyclase. Cells expressing wt-hSSTR3 and mutants
were treated with FSK (20 μM) in the presence or absence of SST-14 (1 μM) and L-
796778 (50 nM) at 37 °C for 30 min and processed for cAMP assay. Note a progressive
loss in the ability of SST-14 or L-796778 to inhibit the FSK-stimulated cAMP in cells
transfected with C-tail mutants in comparison to wt-hSSTR3, which indicates that C-tail
plays an important role in receptor coupling to AC. Data are presented as mean±SE of
three independent experiments. Data analysis was done by using one-way ANOVA and
post hoc Dunnett's test to compare against wt-hSSTR3 (*pb0.05; **pb0.01).
Fig. 4.Microscopic Pb–FRET illustrating HA-hSSTR3 homodimerization. HEK-293 cells expressing HA-hSSTR3 were processed for microscopic Pb–FRET analysis without (A) or with
SST-14 (1 μM) treatment (B) for 10 min at 37 °C. Representative photomicrographs illustrating Cy3-HA-hSSTR3 (red), FITC-HA-hSSTR3 (green) and colocalization (yellow) in HEK-
293 cells in the absence A (i) and presence B (i) of SST-14 treatment. A selection of photomicrographs illustrating photobleaching proﬁle of the cells either expressing donor alone A
(ii) and B (ii) or donor+acceptor A (iv) and B (iv). Histograms representing pixel-by-pixel analysis of time constant of donor alone A (iii) and B (iii) and donor+acceptor A (v) and B
(v). (C) Histogram illustrating a decrease in FRET efﬁciency upon SST-14 and L-796778 treatment suggests decrease of homodimers in response to agonist. Mean±SE is
representative of three independent experiments. Data analysis in (C) was performed by one-way ANOVA and post hoc Dunnett's test to compare against control (**pb0.01).
Table 3
Microscopic Pb–FRET analysis in HEK-293 cells expressing HA-hSSTR3 and treated with
SST-14 and L-796778 for 10 min at 37 °C.
Cell line Treatment τavg (s) n E (%)
HA-hSSTR3 Control D−A 24.18±0.9 48 17±1
D+A 29.12±1 48
SST-14 (1 μM) D−A 24.16±0.6 54 12.2±0.9**
D+A 27.52±0.3 54
L-796778 (50 nM) D−A 24.8±1 42 13.3±1**
D+A 28.6±0.8 42
D−A and D+A indicate donor without and with acceptor, respectively; τavg denotes
average photobleaching time constants; n is the total number of cells analyzed; E (%)
refers to mean effective FRET efﬁciency. Mean±SE is representative of three
independent experiments. Data analysis was performed by using one-way ANOVA
and post hoc Dunnett's test to compare against control (**pb0.01).
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To determine whether hSSTR3 exists as monomer and/or dimer,
microscopic Pb–FRET analysis was performed at cell surface. Cells
expressing HA-hSSTR3 were treated with SST-14 (1 μM) and L-
796778 (50 nM) and processed for Pb–FRET analysis as previously
described [14,17]. As illustrated in Fig. 4A, B, and C and Table 3, HA-
hSSTR3 is a preformed homodimer in basal conditions and displayed a
relative FRET efﬁciency of 17±1%, which was reduced to 12.2±0.9%
and 13.3±1% upon treatment with SST-14 and L-796778, respective-
ly. The decreased effective FRET efﬁciency indicates that HA-hSSTR3
homodimers were decreased upon agonist treatment.
We have previously demonstrated the important role of C-tail in
hSSTR homodimerization [11,14]. To ascertain the role of C-tail
deletion in hSSTR3 on homodimerization, we performedWestern blot
395S.A. War et al. / Biochimica et Biophysica Acta 1813 (2011) 390–402analysis in membrane preparation from cells expressing wt-hSSTR3
and C-tail mutants with or without agonist. As shown in Fig. 5, wt-
hSSTR3 exists as a preformed dimer and the results are consistent
with Pb–FRET analysis. C-tail mutants also displayed homodimeriza-
tion in basal conditions in a comparable manner to wt-hSSTR3.
Receptor dimerization was decreased in the presence of SST-14 and L-
796778 without any signiﬁcant changes in the status of monomers
possibly suggesting the internalization of the receptor as a homo-
dimer as previously described for rSSTR3 [9].3.5. Inﬂuence of hSSTR3 C-tail on ERK1/2 signaling
Having seen the signiﬁcant changes in cAMP inhibition between
wt-hSSTR3 and C-tail mutants, we next determined whether C-tail
deletions in hSSTR3 would affect ERK1/2 phosphorylation. As
illustrated in Fig. 6, p-ERK1/2 expression was decreased upon L-
796778 treatment in cells expressing wt-hSSTR3 and mutants R3
Δ388, R3 Δ342, and R3 ΔCT. On the other hand, SST-14 inhibited p-
ERK1/2 expression only in case of R3 Δ342, and conversely, increased
p-ERK1/2 in R3 Δ415. Interestingly, the basal p-ERK1/2 in wt-hSSTR3Fig. 5. Homodimerization of wt-hSSTR3 and C-tail mutants by Western blot analysis.
HEK-293 cells transfected with wt-hSSTR3 and C-tail mutants were treated with SST-14
(1 μM) and L-796778 (50 nM) for 15 min, and the membrane extract was prepared and
processed for Western blot analysis as described in Materials and methods. The
receptor-speciﬁc band for monomer and homodimer was detected at the expected size
of ~55 and ~110 kDa, respectively. wt-hSSTR3 and C-tail mutants exist as preformed
homodimers at cell membrane. Note the decrease in dimers in wt-hSSTR3 and mutants
upon agonist treatment. These results indicate that agonist-dependent effect on
dimerization is not altered upon C-tail deletion. Densitometry on the bands was
performed, and data represent mean±SE of three independent experiments. Data
analysis was done by using one-way ANOVA and post hoc Dunnett's test to compare
against control (*pb0.05) (data not shown).was less when compared to C-tail mutants suggesting the inhibitory
effect of wt-hSSTR3 on ERK1/2 phosphorylation.
3.6. The role of C-tail in regulation of hSSTR3-mediated inhibition of cell
proliferation
hSSTR3 is known to exert antiproliferative effects [23,26,27]. We
next determined the effect of SST-14 and L-796778 on cell
proliferation in non-transfected HEK-293 cells or cells expressing
wt-hSSTR3 and C-tail mutants, by MTT assay as described in Materials
and methods. As shown in Fig. 7, in wt-hSSTR3 cells, SST-14 and L-
796778 inhibited the cell proliferation by 15±5% and 18.5±8%,
respectively, when compared to control. Comparable results were
obtained in R3 Δ415, as the inhibition of cell proliferation by SST-14
and L-796778 was 16±5% and 17±7%, respectively. Conversely in C-
tail mutants, R3 Δ388, R3 Δ342, and R3 ΔCT, the antiproliferative
effect of SST-14 and L-796778 was lost. No signiﬁcant changes in cell
proliferation were observed in non-transfected cells when treated
with SST-14 or L-796778.
3.7. PARP-1 expression is increased in the presence of SSTR3 selective
agonist
As previously described, hSSTR3-mediated antiproliferative effects
are uniquely triggered by apoptosis [26]. Accordingly, in this
experiment, we determined the expression of PARP-1 as an index of
apoptosis. Cells transfected with wt-hSSTR3 and C-tail mutants were
treated with L-796778 (50 nM) for 24 h at 37 °C and processed for
Western blot analysis for PARP-1 expression. As depicted in Fig. 8, cells
expressing wt-hSSTR3, R3 Δ415, and R3 Δ388 displayed increased
expression of PARP-1 upon treatment with L-796778 when compared
to control. With subsequent deletions in the C-tail (R3 Δ342 and R3
ΔCT), the agonist-induced expression of PARP-1 was completely
abolished, suggesting the failure of agonist mediated apoptosis.
3.8. Increased translocation of PTP-1C to the cell membrane is required
for hSSTR3-mediated apoptosis
Evidence from previous studies has suggested the involvement of
PTP inmediating the antiproliferative actionsby somatostatin receptors,
and this effect is attributed to its translocation to the cell membrane
[5,26,32]. We determined the role of C-tail of hSSTR3 in modulating the
agonist-dependentmembrane translocation of PTP-1C. Cells expressing
wt-hSSTR3 andmutantswere treatedwith SST-14 (1 μM)and L-796778
(50 nM) for 15 min at 37 °C. Membrane and cytosolic fractions were
prepared and processed for PTP-1C expression. As shown in Fig. 9, cells
expressing wt-hSSTR3 displayed an increased membrane expression of
PTP-1C in response to SST-14 and L-796778 when compared with
control. On the other hand, C-tail mutants R3 Δ415, R3 Δ388, and R3
Δ342 displayed no signiﬁcant changes in membrane expression of PTP-
1C in response to agonist treatment. Conversely, agonist treatment in R3
ΔCT decreased PTP-1C expression at themembrane in comparisonwith
control. Furthermore, comparable changes in cytoplasmic expression of
PTP-1Cwere observed inwt-hSSTR3 andmutants. These results provide
evidence that membrane translocation of PTP-1C by hSSTR3 is
abrogated upon C-tail deletion.
3.9. C-tail is the fundamental regulator of hSSTR3-dependent
pro-apoptotic pathways
To further investigate the role of C-tail of hSSTR3 in apoptosis, in
this experiment, we combined the immunostaining of PCNA, a marker
for actively proliferating cells with TUNEL assay for apoptosis. Cells
expressing wt-hSSTR3 and mutants were treated with SST-14 (1 μM)
or L-796778 (50 nM) for 24 h at 37 °C followed by PCNA immuno-
reactivity and TUNEL staining as described in Materials and methods.
Fig. 6.Western blots illustrating ERK1/2 phosphorylation. Cells stably transfected with wt-hSSTR3 and C-tail mutants were treated with SST-14 (1 μM) and L-796778 (50 nM) and
were processed for total and p-ERK1/2 using Western blot analysis as described in Materials and methods. wt-hSSTR3 inhibits ERK1/2 phosphorylation as shown by low p-ERK1/2
levels when compared to C-tail mutants, which exhibit high p-ERK1/2. Densitometry on Western blots for individual ERK1/2 was performed. Data are presented as mean±SE of
three independent experiments. Data analysis was done by using one-way ANOVA and post hoc Dunnett's test to compare against control (*pb0.05).
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TUNEL reaction upon agonist treatment in comparison to non-treated
cells. Interestingly, it was observed that most TUNEL-positive cells
were also PCNA-positive indicating that actively proliferating cells
were susceptible to hSSTR3-mediated apoptosis. With the increasing
amino acid deletions from the C-tail of hSSTR3 (R3 Δ415, R3 Δ388, R3
Δ342, and R3 ΔCT), there was a proportionate loss of TUNEL-positive
cells in response to agonist treatment. These observations strongly
indicate that the apoptotic activity of hSSTR3 is conserved in the
amino acid residues present in the C-tail.
4. Discussion
The aim of the present study was to determine the role of hSSTR3
C-tail on the physiological response of cell in presence of ligand. To
ascertain this, the experiment was designed in HEK-293 cells stablytransfected with wt-hSSTR3 and C-tail mutants of hSSTR3 and studied
for receptor internalization, coupling to AC and modulation of
downstream signaling pathways regulating cell proliferation and
apoptosis. In addition, we also described hSSTR3 dimerization with or
without agonist. To the best of our knowledge, this is the ﬁrst study
describing a comprehensive characterization of hSSTR3.
Receptor binding analysis and immunocytochemistry indicate no
signiﬁcant differences in the membrane expression between wt-
hSSTR3 and C-tail mutants. The receptor expression in C-tail mutants
was sufﬁcient to demonstrate comparable signaling properties, as
described earlier for SSTR5 mutants [28,33]. Furthermore, the
receptor density in wt-hSSTR3 and mutants is within the range of
physiological SSTR expression [8,34]. We have previously shown that
C-tail deletions of hSSTR5 did not affect the ligand binding [35].
Several previous studies have also described that the ligand binding
domain in GPCRs is conﬁned in the extracellular loops and/or
Fig. 7. The role of C-tail deletion on cell proliferation. HEK-293 cells expressing wt-hSSTR3 and C-tail mutants were treated with SST-14 (1 μM) and L-796778 (50nM) for 24 h before
processing for MTT assay as described inMaterials andmethods. SST-14 and L-796778 inhibited cell proliferation in wt-hSSTR3 and R3Δ415, while this effect was lost in R3Δ388, R3
Δ342, and R3 ΔCT, indicating that C-tail plays a decisive role on cell proliferation. Mean±SE representative of three independent experiments. Data analysis was done by using one-
way ANOVA and post hoc Dunnett's test to compare against control (*pb0.05; **pb0.01).
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strate no signiﬁcant changes in ligand binding upon C-tail deletions in
hSSTR3, suggesting that the absence of C-tail fails to exert any
signiﬁcant effect on binding. SSTR subtypes respond to agonist
treatment and internalize in time-, temperature-, and receptor-
speciﬁc manner. Our data demonstrate no signiﬁcant differences in
receptor internalization between wt-hSSTR3 and C-tail mutants in
response to SST-14 or the receptor speciﬁc agonist, which suggests
that hSSTR3 C-tail does not play any key role in receptor internali-
zation. These results are in contrast to a previous study on rSSTR3
where mutations in the C-tail signiﬁcantly altered the rate and extent
of receptor internalization [40]. Interestingly, hSSTRs and rSSTRs
exhibit distinct and diverse response to agonist in modulation of
receptor internalization and signaling pathways and this discrepancy
is likely due to species difference [9,41–44].
Our previous studies have shown distinct receptor-speciﬁc homo-
and heterodimerization of hSSTR subtypes [7,8,10–14]. Most impor-
tantly, all ﬁve SSTRs with the exception of hSSTR1 exhibit receptor-
speciﬁc homodimerization, which is also attributed to the functional
consequences [7–11,14,17]. As shown earlier, rSSTR3 is a constitutive
homodimer at cell surface and C-tail of rSSTR3 was not essential for
homodimerization [9]. Previous studies have shown that metabo-
tropic glutamate receptor 5 and calcium-sensing receptor undergo
dimerization via extracellular amino terminal domain [45,46].
Cumulatively, these data suggest that C-tail is not essential require-ment for GPCR dimerization. This notion is supported by our data
showing homodimerization in wt-hSSTR3 and C-tail mutants. The
molecular mechanism of hSSTR3 homodimerization still remains
unclear and needs to be further elucidated. The decreased relative
FRET efﬁciency observed in wt-hSSTR3 in presence of SST-14 and
SSTR3-speciﬁc agonist might be attributed to the receptor internal-
ization as dimer. FRET efﬁciency is directly related to the distance and
receptor orientation at the cell surface. The loss in FRET efﬁciency in
presence of agonist might also be due to conformational changes as
well as receptor orientation at the plasma membrane.
There aremounting evidence showing critical role of C-tail in GPCR
functioning [14,35,40,47–51]. Our previous studies have shown
concentration-dependent effect of SST-14 on the inhibition of FSK-
stimulated cAMP and SST-14 in range of 0.1–1 μMwas found to exert
maximal effect [11,35,52]. Consistent with these observations, FSK-
stimulated cAMP was signiﬁcantly inhibited in cells expressing wt-
hSSTR3, and the results are further supported by several previous
studies [9,53,54]. The ability of SST-14 or SSTR3 agonist to inhibit
cAMP was proportionally lost with amino acids deleted from the C-
tail. This is in agreement with our previous studies where we have
shown the loss of receptor coupling to AC in C-tail deleted hSSTR5 and
hSSTR4 [8,14,35].
Several previous studies have shown that activation of GPCRs by
agonist plays a determinant role on phosphorylation of ERK1/2 and
the changes in status of ERK phosphorylation are directly implicated
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The inhibition of basal ERK activity has been shown to trigger
apoptosis in HeLa cells [57]. We have recently shown increased ERK1/
2 phosphorylation upon C-tail deletion in hSSTR4 [14]. Our results
demonstrate reduced pERK1/2 in cells expressing wt-hSSTR3, R3
Δ388, R3 Δ342, and R3 ΔCT in response to receptor-speciﬁc agonist.
On the other hand, SST-14 increased ERK1/2 in R3 Δ415 expressing
cells, while inhibiting p-ERK1/2 only in cells transfectedwith R3Δ342.
These diverse effects on ERK1/2 phosphorylation between wt-hSSTR3
andmutants might be attributed to distinct role in signaling played by
amino acids in the C-tail as previously described for follicle
stimulating hormone receptor (FSHR) [58]. Most signiﬁcantly, cells
expressing wt-hSSTR3 exhibited decreased p-ERK1/2 when compared
to C-tail mutants, indicating that wt-hSSTR3 has an inhibitory
inﬂuence on ERK1/2 phosphorylation, an effect that was not evident
in C-tail mutants. The high basal p- ERK1/2 in C-tail mutants may be
due to activation of signaling pathways, which are G-protein-
independent, as demonstrated previously for β2-adrenergic receptor
[59]. Accordingly, the distinct regulation of ERK1/2 in the presence of
SST-14- and SSTR3-speciﬁc agonist might be due to SST-14 mediated
activation in pertussis toxin-insensitive manner and cannot be
excluded from discussion.
The antiproliferative effect mediated by SSTRs is receptor-speciﬁc
phenomenon either associated with blocking cell growth or activating
cytotoxic pathways [5,21,26,28,29]. In the present study, MTT assay
provides direct evidence for agonist mediated inhibition of cell
proliferation in wt-hSSTR3 and R3 Δ415, an effect that was lost in
other C-tail mutants. It is, however, unclear whether hSSTR3-
mediated antiproliferative effects are dependent upon p-ERK1/2
inhibition. Importantly, MTT assay was accomplished after 24-Fig. 8. Immunoblots illustrating the expression of PARP-1. Stable transfectants of wt-hSSTR3 a
1 expression as described in Materials and methods. The receptor-speciﬁc agonist mediated
effect was completely lost in R3 Δ342 and R3 ΔCT. Camptothecin-treated Jurkat cell lysate w
Histograms illustrate the changes in PARP-1 activation. Data are presented as mean±SE of t
compare treatment with control (*pb0.05; **pb0.01). Statistical analysis was performed
#pb0.001).h treatment, whereas ERK1/2 was studied only after 5- or 15-min
treatment. A diverse cellular response to transient or sustained ERK
activation could possibly lead to this inconsistency. Moreover, the
biological effects of ERK1/2 activation are not only sensitive to cell
types, extracellular factors, and the receptors involved but also on the
amplitude and duration of ERK1/2 activation [23]. In case of hSSTR
mediated cytotoxic effect, the translocation of PTP from cytosol to the
cell membrane and increased expression of PARP-1 are considered to
be essential steps [60–62]. Our data demonstrate an increase in
agonist-induced PTP-1C translocation to the cell surface in wt-hSSTR3
with a parallel increase in PARP-1 expression. All these events directly
support the antiproliferative effects of hSSTR3 through cytotoxic
mode of cell death. We further correlated changes in PTP-1C and
PARP-1 activation by in situ TUNEL assay for apoptosis. Our results
demonstrate that in the presence of SST-14 or L-796778, a SSTR3-
speciﬁc agonist, only cells positive to PCNA exhibit TUNEL staining
indicating that actively proliferating cells are more vulnerable to
apoptosis, an observation not described previously. Most importantly,
membrane expression of PTP-1C is completely lost in cells transfected
with C-tail mutants, which is accompanied by an increase in p-ERK1/
2. These ﬁndings suggest that PTP-1C regulates ERK1/2 phosphory-
lation as also previously reported [21]. PARP-1 activation is lost in
cells expressing R3 Δ342 and R3 ΔCT. In R3 Δ388 expressing cells,
despite PARP-1 expression, there were no signiﬁcant changes in cell
proliferation most likely due to high p-ERK1/2 levels opposing the
antiproliferative activity by agonist in this mutant.
The molecular mechanism and the speciﬁc motif in the C-tail that
are responsible for receptor trafﬁcking, coupling to AC and most
importantly, the pro-apoptotic response of hSSTR3 are still elusive
and further studies are in progress in this direction. Moreover, the rolend C-tail mutants were treated with L-796778 (50nM) for 24 h and processed for PARP-
activation of PARP-1 in wt-hSSTR3, R3 Δ415, and R3 Δ388 conﬁrms apoptosis, and this
as used as positive control for PARP-1. β-Actin was used as a control for protein loading.
hree independent experiments. Data analysis was done using student unpaired t-test to
by one-way ANOVA and post hoc Dunnett's test to compare against wt-hSSTR3 (#
Fig. 9.Western blots showingmembrane and cytosolic expression of PTP-1C. HEK-293 cells expressing wt-hSSTR3 and C-tail mutants were treated with SST-14 (1 μM) and L-796778
(50 nM) for 15 min. Membrane and cytosolic extract was processed for PTP-1C expression as described in Materials and methods. Panels (A) and (C) represent immunoblots
displaying PTP-1C expression in the membrane and cytosol, respectively. Note the increased membrane expression of PTP-1C in response to SST-14 and L-796778 treatment in wt-
hSSTR3, and conversely, in C-tail mutants, this effect is signiﬁcantly lost. These results suggest that C-tail is essential for membrane translocation of PTP-1C. Densitometric analysis
performed on the bands shown in (A) and (C) to determine changes in PTP-1C expression are illustrated in panels (B) and (D), respectively. Results represent mean±SE of three
independent experiments. Data analysis was done by using one-way ANOVA and post hoc Dunnett's test to compare against control (*pb0.05).
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be ruled out as we have recently demonstrated [13]. A detailed
analysis of hSSTR3 revealed that there was a gradual increase in the
proportion of acidic amino acids upon deletions in the C-tail. Previous
studies have implicated the critical role of basic amino acids present in
the C-tail of GPCRs on receptor function. Comparative studies on the
human class 1 GPCRs have indicated the presence of the conserved
positively charged amino acid sequences in the C-tail adjacent to the
7TM region [63]. In addition, mutations in the Arginine and Lysine
residues in the C-tail of melanocorticotropin hormone receptor-1
(MCHR-1) resulted in the variable changes in the receptor expression
and function [63]. Consistent with these studies, C-tail of hSSTR3
contains 18 basic aa and their gradual loss in the truncated mutants
might be responsible for the loss of receptor function. In accordance,
the loss of 4 and 10 basic aa from hSSTR3 mutants R3 Δ388 and R3
Δ342 respectively might directly correlate with the loss of receptor
signaling.
C-tail of hSSTR3 constitutes approximately 100 aa containing 11
Serine and 6 Threonine residues other than 37 charged aa residues.
Loss of one Serine residue in the R3 Δ415 resulted in decreasedinhibition of FSK-stimulated cAMP upon agonist activation by N15% in
comparison to the wt-hSSTR3 suggesting the loss of potential
phosphorylation site. Recent study on wt-FSHR has demonstrated
that truncation at 635th residue in the C-tail removes all potential
phosphorylation sites except one and the mutant FSHR behaves more
efﬁciently than the wt-FSHR. The authors claimed that this unexpect-
ed behavior was due to the exposure of potential phosphorylation
sites in the mutant receptor, which were not readily accessible in the
wt-FSHR [58]. Taken into consideration, this might as well be true for
hSSTR3 mutants, in which the non-accessible potential phosphoryla-
tion sites were exposed upon deletion possibly leading to distinct
response of the mutants on ERK1/2 phosphorylation and PARP-1
activation.
In summary, we have shown that the deletion of amino acids from
the C-tail of hSSTR3 appears to alter the physiological response of cells
to agonist. C-tail deletions in hSSTR3 inhibit the normal receptor
function in cells. There are many questions yet to be answered with
the results emerging from this study, like why only PCNA-positive
cells are susceptible to SST-14- and SSTR3-speciﬁc agonist-induced
apoptosis, and to address such a complicated scenario, further studies
Fig. 10. Representative photomicrographs showing colocalization of PCNA- and TUNEL-positive HEK-293 cells. (A) HEK-293 cells transfected with wt-hSSTR3 and C-tail mutants
were treated with SST-14 (1 μM) and L-796778 (50 nM) for 24 h and were processed for PCNA immunoﬂuorescence and TUNEL staining (please see Materials and methods for
details). wt-hSSTR3 cells exhibiting PCNA immunoreactivity undergo agonist-induced apoptosis as evident by increased TUNEL-positive reaction. Cells expressing C-tail mutants
display signiﬁcant loss in TUNEL reactivity, which suggests decreased pro-apoptotic activity. These ﬁndings implicate a key role for hSSTR3 C-tail in mediating agonist-dependent
apoptosis. Arrows indicate colocalization of PCNA- and TUNEL-positive cells. Scale bar=10 μm. (B) Histograms represent percent of cells showing positive PCNA and TUNEL reaction.
A total of 500–800 cells were counted for each treatment condition. Results are expressed as mean±SE of three independent experiments. Data analysis was performed by one-way
ANOVA and post hoc Dunnett's test to compare against control (*pb0.05; **pb0.01).
400 S.A. War et al. / Biochimica et Biophysica Acta 1813 (2011) 390–402are required in time to come. Most importantly, data presented in this
study describe some previously unnoticed role of hSSTR3, which was
not explored earlier.
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